DNA damage regulates ARID1A stability via SCF ubiquitin ligase in gastric cancer cells

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 17, 2015, Pages 3194-3200

  Jiang, Z H ^a   Dong, X W ^a   Shen, Y C ^a   Qian, H L ^a   Yan, M ^a   Yu, Z H ^a   He, H B ^a   Lu, C D ^a   Qiu, F ^a  

^a Lihuili Hospital   (China)

Author keywords

ARID1A; Gastric cancer; Scf e3 ligase; Ubiquitination.

Indexed keywords

AT RICH INTERACTIVE DOMAIN 1A; CASPASE 3; CULLIN SKP1 F BOX PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUCLEAR PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ARID1A PROTEIN, HUMAN; TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE;

ARID1A GENE; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; GASTRIC CANCER CELL LINE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STABILITY; TRANSCRIPTION REGULATION; UBIQUITINATION; APOPTOSIS; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; DNA DAMAGE; HUMANS; NUCLEAR PROTEINS; SKP CULLIN F-BOX PROTEIN LIGASES; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84973434437     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. RAHMAN R, ASOMBANG AW, IBDAH JA. Characteristics of gastric cancer in Asia. World J Gastroenterol 2014; 20: 4483-4490.
2. LU B, LI M. Helicobacter pylori eradication for preventing gastric cancer. World J Gastroenterol 2014; 20: 5660-5665.
3. VENERITO M, NARDONE G, SELGRAD M, ROKKAS T, MALFERTHEINER P. Gastric cancer-epidemiologic and clinical aspects. Helicobacter 2014; 19 Suppl 1: 32-37.
4. FUKAYAMA M. Epstein-Barr virus and gastric carcinoma. Pathol Int 2010; 60: 337-350.
5. WAGIH HM, EL-AGEERY SM, ALGHAITHY AA. A study of RUNX3, E-cadherin and beta-catenin in CagApositive Helicobacter pylori associated chronic gastritis in Saudi patients. Eur Rev Med Pharmacol Sci 2015; 19: 1416-1429.
6. SHI J, QU YP, HOU P. Pathogenetic mechanisms in gastric cancer. World J Gastroenterol 2014; 20: 13804-13819.
7. QU Y, DANG S, HOU P. Gene methylation in gastric cancer. Clin Chim Acta 2013; 424: 53-65.
8. FUKAYAMA M, USHIKU T. Epstein-Barr virus-associated gastric carcinoma. Pathol Res Pract 2011; 207: 529-537.
9. WILSON BG, ROBERTS CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011; 11: 481-492.
10. SAMARTZIS EP, NOSKE A, DEDES KJ, FINK D, IMESCH P. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci 2013; 14: 18824-18849.
11. RAHMAN MT, NAKAYAMA K, RAHMAN M, ISHIKAWA M, KATAGIRI H, KATAGIRI A, ISHIBASHI T, SATO E, IIDA K, ISHIKAWA N, NAKAYAMA N, MIYAZAKI K. ESR1 gene amplification in endometrial carcinomas: a clinicopathological analysis. Anticancer Res 2013; 33: 3775-3781.
12. SHIGETOMI H, OONOGI A, TSUNEMI T, TANASE Y, YAMADA Y, KAJIHARA H, YOSHIZAWA Y, FURUKAWA N, HARUTA S, YOSHIDA S, SADO T, OI H, KOBAYASHI H. The role of components of the chromatin modification machinery in carcinogenesis of clear cell carcinoma of the ovary (Review. Oncol Lett 2011; 2: 591-597.
13. WU JN, ROBERTS CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov 2013; 3: 35-43.
14. WU RC, WANG TL, SHIH IE M. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther 2014; 15: 655-664.
15. ABE H, MAEDA D, HINO R, OTAKE Y, ISOGAI M, USHIKU AS, MATSUSAKA K, KUNITA A, USHIKU T, UOZAKI H, TATEISHI Y, HISHIMA T, IWASAKI Y, ISHIKAWA S, FUKAYAMA M. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch 2012; 461: 367-377.
16. THIEL A, RISTIMAKI A. Gastric cancer: basic aspects. Helicobacter 2012; 17 Suppl 1: 26-29.
17. LEE EK, DIEHL JA. SCFs in the new millennium. Oncogene 2014; 33: 2011-2018.
18. SKAAR JR, PAGAN JK, PAGANO M. SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov 2014; 13: 889-903.
19. SOUCY TA, SMITH PG, MILHOLLEN MA, BERGER AJ, GAVIN JM, ADHIKARI S, BROWNELL JE, BURKE KE, CARDIN DP, CRITCHLEY S, CULLIS CA, DOUCETTE A, GAR-NSEY JJ, GAULIN JL, GERSHMAN RE, LUBLINSKY AR, MC-DONALD A, MIZUTANI H, NARAYANAN U, OLHAVA EJ, PELUSO S, REZAEI M, SINTCHAK MD, TALREJA T, THOMAS MP, TRAORE T, VYSKOCIL S, WEATHERHEAD GS, YU J, ZHANG J, DICK LR, CLAIBORNE CF, ROLFE M, BOLEN JB, LANGSTON SP. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-736.
20. ALLO G, BERNARDINI MQ, WU RC, SHIH IE M, KALLOGER S, POLLETT A, GILKS CB, CLARKE BA. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol 2014; 27: 255-261.
21. CHOU A, TOON CW, CLARKSON A, SIOSON L, HOUANG M, WATSON N, DESILVA K, GILL AJ. Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum Pathol 2014; 45: 1697-1703.
22. SIMPSON AJ, CABALLERO OL, PENA SD. Microsatellite instability as a tool for the classification of gastric cancer. Trends Mol Med 2001; 7: 76-80.
23. GOLOGAN A, SEPULVEDA AR. Microsatellite instability and DNA mismatch repair deficiency testing in hereditary and sporadic gastrointestinal cancers. Clin Lab Med 2005; 25: 179-196.